initial public offerings (IPOs) trading on American exchanges

Monday, January 5, 2015

Vitae Pharmaceuticals (VTAE) began trading on the NASDAQ on 24 September 2014


Vitae Pharmaceuticals, Inc. is a clinical stage biotechnology company. The Company is focused on discovering and developing small molecule drugs for diseases. The Company’s product candidates include VTP-34072, VTP-37948, VTP-4374, VTP-38443 and VTP-38543. VTP-34072 is being developed for type II diabetes. VTP-34072 is designed to inhibit 11b hydroxysteroid dehydrogenase type II, or 11b HSD1, the enzyme responsible for production of cortisol in tissues where active glucose metabolism takes place, including the liver and adipose, or fat, tissue. VTP-37948 is being developed for treatment of Alzheimer's. Alzheimer's is characterized by the accumulation of extracellular protein deposits in the brain that are called amyloid plaques.


502 W Office Center Dr
United States

Key stats and ratios

Q3 (Sep '14)2013
Net profit margin-29.29%5.16%
Operating margin-27.80%9.73%
EBITD margin-10.64%
Return on average assets-16.05%3.35%
Return on average equity--

No comments:

Post a Comment